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Abstract A better understanding of the economic burden of
diabetes constitutes a major public health challenge in order
to design new ways to curb diabetes health care expenditure.
The aim of this study was to develop a new cost-of-illness
method in order to assess the specific and nonspecific costs of
diabetes from a public payer perspective. Using medical and
administrative data from the major French national health
insurance system covering about 59 million individuals in
2012, we identified people with diabetes and then estimated
the economic burden of diabetes. Various methods were
used: (a) global cost of patients with diabetes, (b) cost of
treatment directly related to diabetes (i.e., ‘medicalized
approach’), (c) incremental regression-based approach,
(d) incremental matched-control approach, and (e) a novel
combination of the ‘medicalized approach’ and the ‘incre-
mental matched-control’ approach. We identified 3 million
individuals with diabetes (5% of the population). The total
expenditure of this population amounted to €19 billion,
representing 15% of total expenditure reimbursed to the
entire population. Of the total expenditure, €10 billion (52%)
was considered to be attributable to diabetes care: €2.3 bil-
lion (23% of €10 billion) was directly attributable, and €7.7
billion was attributable to additional reimbursed expenditure
indirectly related to diabetes (77%). Inpatient care repre-
sented the major part of the expenditure attributable to
diabetes care (22%) together with drugs (20%) and medical
auxiliaries (15%). Antidiabetic drugs represented an
expenditure of about €1.1 billion, accounting for 49% of all
diabetes-specific expenditure. This study shows the eco-
nomic impact of the assumption concerning definition of
costs on evaluation of the economic burden of diabetes. The
proposed new cost-of-illness method provides specific
insight for policy-makers to enhance diabetes management
and assess the opportunity costs of diabetes complications’
management programs.
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Introduction
A better understanding of the economic burden of diabetes
constitutes a major public health challenge for health
insurers in order to identify ways to improve diabetes
follow-up and control the dynamics of diabetes-related
expenditure [1–3]. In France, diabetes is a major public
health problem, as about 3 million patients who received
care for diabetes in 2012, i.e., 4.6% of the whole popula-
tion [1]. In view of the growing prevalence of the main risk
factors for diabetes (ageing of the population, obesity, and
sedentary lifestyle), as well as the growing population, this
situation is likely to worsen with time [1, 4–7]. The
severity of diabetic complications, such as cardiovascular
disease, renal failure, and amputations [2], and the asso-
ciation between diabetes and excess risk of other chronic
diseases such as certain cancers [3], justify active man-
agement of this disease [1].
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The scope of costs included to evaluate the economic
burden of a disease is the subject of intense discussion in
the literature [8–13]. When the definition of costs is
restricted to health care expenditure, excluding costs rela-
ted to impaired quality of life, there is still a persistent
debate between supporters of a comprehensive expenditure
approach and supporters of a more restrictive approach,
targeted to specific expenditure related to management of
the disease. Between these two extremes, an intermediate,
so-called incremental, definition has also been widely used
[12, 13]. This method consists of measuring the excess
expenditure related to the disease by comparing the
expenditure of individuals with the disease to that of
individuals without the disease but presenting similar
demographic and socioeconomic characteristics in order to
isolate the costs specifically due to the disease.
The three most commonly used expenditure-based
approaches [8] address different and complementary eco-
nomic and epidemiological questions. First, the global
comprehensive approach provides an overall picture of all
expenditure of a population with a particular disease (type
of care, concentration, dispersion), whether or not this
expenditure is related to the disease [6]. Second, medical-
ized approaches can be used to distinguish expenditure that
is highly specific to the disease from other types of
expenditure, with an a priori definition of specific expen-
diture. These approaches provide insight into the costs of
the various types of care used to treat the disease. Third,
incremental approaches can be used to distinguish over-
consumption of a particular population due to the illness,
its complications and the impaired health status related to
the disease. These methods can be used to estimate the
overall costs of the disease without identifying, ex-ante, the
expenditure specifically related to the disease.
The present study was designed to contribute to the
international literature by comparing the various approa-
ches recently used in cost-of-illness studies to evaluate the
financial burden of diabetes [14]. It also presents a new
approach based on a combination of existing methods to
distinguish direct costs specifically due to diabetes by
means of a medicalized approach from costs related to
complications and impaired health status by means of an
incremental approach. In particular, we identified reim-
bursements specific to antidiabetic treatments, as well as
reimbursements related to the main complications of dia-
betes (cardiovascular diseases and chronic renal failure).
Reimbursements of diabetes-related health care expendi-
ture were extracted from the Syste`me National d’Infor-
mation InterRe´gimes de l’Assurance Maladie [National
Health Insurance Information System] (SNIIRAM) data-
base in 2012 [15].
In the following section, we will describe the data used
for this study. We will then describe the methodology used
to estimate national health insurance reimbursements
effectively related to diabetes. Finally, the results of the
study will be presented, followed by a discussion.
Data
The Syste`me National d’Information InterRe´gimes de
l’Assurance Maladie [National Health Insurance Informa-
tion System] (SNIIRAM), designed to provide a better
understanding and more accurate evaluation of quality of
care, health care use and associated expenditure, was set up
in France in the early 2000s [15]. While some adminis-
trative databases in other countries are only representative
of a subpopulation (e.g., in the U.S., Medicare data are
representative of individuals 65 years and older), the
SNIIRAM database contains data on all reimbursed health
care expenditure (inpatient, outpatient, and cash payments)
for the entire population living in France. It also includes
sociodemographic, medical, and administrative data con-
cerning these beneficiaries (age, gender, diagnoses of long-
term diseases eligible for 100% reimbursement, diagnoses
reported during hospitalizations, town of residence, date of
death) [15]. The SNIIRAM database is therefore probably
one of the largest national health databases in the world, in
contrast to databases in northern European countries, in
which data are representative of the entire population, but
based on a smaller number of observations.
Reimbursements of diabetes-related health care expendi-
ture were extracted from the SNIIRAM database in 2012 for
people insured by the French health insurance general
scheme and local schemes (86% of the French population, 59
million individuals), with the approval of the French data
protection authority (Commission Nationale Informatique et
Liberte´). The French health insurance general scheme covers
salaried workers, retired private sector individuals, and, more
generally, all individuals not covered by a specific scheme
(farmers, self-employed, special schemes), and their relatives
(76% of the population living in France). Local schemes
provide health insurance coverage for civil servants, students,
and hospital staff (10% of the population living in France).
The scope of expenditure considered in this study
included outpatient care (office visits, drugs, medical
devices, nursing care, laboratory tests), and hospital
expenditure, including public and private medical, surgical
and obstetric (MSO) hospital stays, aftercare and rehabil-
itation (CR) and psychiatric admissions. Cash payments,
such as daily allowances or disability pensions were also
taken into account, but only for those paid by the general
scheme, as data from local schemes may be incomplete or
missing. The expenditure studied in this paper represented
a total of €124 billion in 2012 that can be linked to general
health scheme and local scheme beneficiaries.
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Method
Identification and characteristics of the diabetic
population in 2012
An algorithm was used to qualify a patient as diabetic if
and only if this patient had received at least three reim-
bursements for antidiabetic drugs (oral or insulin) in 2012
(at least two reimbursements if at least one large pack size
was dispensed), or in 2011 in order to avoid censorship
effects, or when this patient had been allocated long-term
disease (LTD) status for diabetes in 2012. The list of
antidiabetic drugs corresponds to class A10 of the
Anatomical Therapeutic Chemical (ATC) classification,
with the exception of benfluorex [16]. In addition to age
and gender, two variables were used as a proxy to char-
acterize the individual’s financial situation: complementary
universal health insurance coverage (CMU-C) and an
ecological deprivation index [17, 18]. Complementary
universal health insurance coverage (‘‘couverture maladie
universelle comple´mentaire’’ or CMU-C) is provided by
national health insurance schemes to people with incomes
lower than a defined ceiling (€7934 for a single person as
of July 2012). The deprivation index reflects a major part
of spatial socioeconomic heterogeneity based on four
indicators (median household income, percentage of high
school graduates in the population aged 15 years and older,
percentage of blue-collar workers in the active population,
and the unemployment rate) homogeneously throughout
metropolitan France. This index is routinely used to
observe, analyze, and manage spatial health inequalities.
Definitions of the scope of diabetes-related
reimbursed expenditure
Three main methods that have been recently used to estimate
the financial burden of a disease [8] were used in this study
(Table 1). In addition, for the first time in the literature to the
best of our knowledge, a combination of two of thesemethods
was used in order to propose a new approach (Method 4).
Method 1: global comprehensive definition
The global comprehensive definition was initially adopted
in order to establish an estimate of all expenditure (for
diabetes or for any other disease) reimbursed to patients
with diabetes and to therefore characterize the burden of
reimbursements paid to these patients compared to all
reimbursements to all patients [8]. The sum of all expen-
diture reimbursed to patients with diabetes was calculated.
This global comprehensive analysis also allows a descrip-
tion of types of care used and the distribution of annual
expenditure reimbursed to patients (mean, dispersion,
concentration of expenditure).
Method 2: medicalized approach
In the context of the medicalized approach, reimbursements
paid to the diabetic population for diabetes-specific expendi-
ture were entirely and directly attributed to diabetes. The
following types of outpatient expenditure were considered to
be diabetes-specific: endocrinologist visits, reimbursements
of medical devices on the ‘‘Liste des Produits et des Presta-
tions remboursables’’ (LPP) [List of reimbursed medical
devices and services] intrinsically related to diabetes (dip-
sticks, insulin pens, and insulin pump materials), reimburse-
ments of antidiabetic drugs (oral and insulin), reimbursements
of blood glucose, and glycated hemoglobin (HbA1c) assays
and reimbursements of podiatrist fees (fee set up by national
health insurance to improve the prevention of diabetic foot
lesions for patients at high risk). For inpatient care, reim-
bursements related to Medicine, Surgery, and Obstetrics
(MSO) hospital stays for diabetes (as a principal or related
diagnosis, corresponding to codes E10-E14 of the Interna-
tional Classification of Diseases, Tenth edition) were con-
sidered to be diabetes-specific and were also entirely
attributed to diabetes-related reimbursements. The expendi-
ture observed for patients not identified as having diabetes
according to the algorithm, but who were admitted to hospital
with a diagnosis of diabetes in 2012 (as a principal or related
diagnosis) or who had received at least one reimbursement of
podiatrist fees for diabetes in 2012 was also added to the
diabetes-specific expenditure (to compensate for incomplete
detection by the algorithm of a small number of patients with
diabetes).
Method 3: incremental approach
The incremental approach includes both a regression-based
approach and a matched-control approach, in which a
control group of patients without the disease is used to
estimate the cost of illness.
Method 3.1: regression-based incremental approach
The regression-based incremental approach is also com-
monly used in the literature [10, 12, 19]. A large number of
papers have been published on modeling of health care
expenditure in order to take into account two important
characteristics of the distribution of health care expendi-
ture: the large number of subjects with zero expenditure
and the highly-skewed distribution (for a formal descrip-
tion of the various challenges involved in health care
expenditure estimation models refer to [20–22]). The var-
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ious models reported in the literature comprise two equa-
tions designed to take zero expenditure into account. The
first equation models the individual’s decision to access
health care services, i.e., the probability of having health
care expenditure different from zero. The second equation
determines the level of health care consumption in the
subsample of individuals with health care expenditure
different from zero.
These two equations can be estimated according to two
models depending on the economic hypothesis adopted to
characterize the relationship between the decision to access
health care and the level of health care consumption. The
Sample Selection Model is based on the hypothesis of a
correlation between the two decisions. The second type of
model is the Two-Part Model. This model is based on the
hypothesis that the decision to access health care and the
level of health care consumption are not correlated and that
these two equations are independent. The Two-Part Model
cannot conclude on a causal inference between exogenous
variables and the level of health care expenditure because
this model does not take into account individual hetero-
geneity, which certainly influences the probability of health
care consumption and the level of health care consumption.
However, the Two-Part Model is sufficient for prediction
of health care expenditure, as this calculation does not
analyze the effect of a particular variable [22].
The objective of the present studywas to simulate themean
level of health care expenditure of the population rather than
interpret and analyze coefficients of health care demand.
Consequently, we adopted the hypothesis that there is no
relationship between the decision to access health care and the
level of health care consumption. We therefore exclusively
estimated the second part of a Two-Part Model concerning
only those people with at least one reimbursement detected in
the SNIIRAMdatabase. The level of health care consumption
was estimated by the generalized linear model (GLM). We
chose the most appropriate link function for our data log-link
with a gamma distribution and tested the goodness of fit of this
model [10] (see goodness of fit test results in Appendix 1).
The vector of control variables is composed of age,
gender, and diabetes status. In order to calculate the annual
spending attributable to diabetes, annual spending was
initially predicted by using the coefficients of the GLM
estimation using a GLM specification where Di is health-
care spending and X1,i are the explanatory variables used in
the estimation. Health care consumption is predicted by:
E^ðDijX1;iÞ ¼ expðX01;i ^bÞ:
The hypothetical health care expenditure of patients
with diabetes if they did not have diabetes was then esti-
mated by applying a coefficient of 0 associated with dia-
betes in the health care expenditure equation. Diabetes-
specific expenditure was estimated by the mean difference
between these two predictions [10].
Method 3.2: matched-control incremental approach
Amatched-control incremental approach was then performed
for all spending to determine the impact of diabetes on health
care expenditure [23, 24]. According to this method, the
excess reimbursements attributable to diabetesweremeasured
by determining the differential between reimbursements paid
to patients with diabetes and those without diabetes. To cal-
culate this excess reimbursement, we defined a control group
of patients without diabetes stratified by 10-year age groups.
The excess reimbursements related to diabetes were therefore
estimated for each age-group as the difference between the
expenditure of the diabetes population (case) and the expen-
diture of the population without diabetes (control). In other
words, the reimbursed expenditure differential was estimated
by gender and by 10-year age groups. Ten-year age groups
were used rather than exact age groups in order to allow
regional analysis of diabetes expenditure by means of the
same methodology with a sufficient number of individuals in
each group to provide significant and robust results. As the
incremental approach is designed to identify costs that are
causally related to diabetes (such as the costs related to
complications of diabetes), no adjustment can be performed
for variables causally related to diabetes.
Method 4: combination of medicalized and incremental
approaches
Lastly, the global medicalized and matched-control incre-
mental definitions were used in combination (Table 1) to
distinguish health care expenditure specific to the man-
agement of diabetes (using the global medicalized
approach) from that related to management of complica-
tions and/or excess health care consumption induced by
impaired health status due to diabetes (using the incre-
mental approach). Both of these methods have been used
previously [10], but not necessarily in the same study in
order to provide a better understanding of the expenditure
attributable to diabetes. Firstly, diabetes-specific expendi-
ture was entirely and directly attributed to diabetes
according to the medicalized approach. Secondly, the
matched-control incremental approach was then performed
on the overall population to determine the impact of dia-
betes on the rest of health care expenditure (not specific to
diabetes), as diabetes is a risk factor for certain chronic
diseases. Excess reimbursements for diabetes-related
complications, matched for age and gender, represent the
cost of developing a specific disease for a patient with
diabetes. The implicit hypothesis is that if diabetes com-
G. Lagasnerie et al.
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plications could be eradicated, excess reimbursements
would be zero. However, this simplifying assumption is not
fully met, as factors other than age and gender may also be
involved in the comparison between the health care
expenditure of patients with or without diabetes [16, 25].
Results
Characteristics of the diabetic population in 2012
According to the algorithm used in this study, 2.9 million
people with diabetes were identified among the 59 million
general health scheme and local scheme beneficiaries in
2012. The main characteristics of patients with diabetes
identified by this algorithm are described in Table 2. As
expected, these patients were older than the general pop-
ulation with a mean age of 66 years versus 39 years, as the
prevalence of diabetes increases very markedly with age.
Diabetes also appears to be related to socioeconomic
markers, as an over-representation of people with diabetes
was observed in territories with lower socioeconomic sta-
tus. One quarter of patients with diabetes in 2012 lived in
territories with the lowest socioeconomic quintile (versus
20% for the general population) and only 16% lived in
territories with the highest socioeconomic quintile.
Global comprehensive approach: reimbursements
paid to patients with diabetes
The sum of all reimbursements (health care consump-
tion, daily allowances and disability pensions) for
patients with diabetes, whether or not the expenditure
was related to diabetes, was €19 billion, i.e., 15% of all
general health scheme and local scheme reimbursements
(€124 billion).
In 2012, patients with diabetes (mean age: 66 years)
therefore received an average of €6714 of health insurance
reimbursements. Hospital expenditure represented 42% of
all reimbursements, pharmacy expenditure represented
21% and other outpatient care (medical fees, nursing care
etc.) represented 31%, and cash payments (daily allowan-
ces and disability pensions) represented 6% of all reim-
bursements (Fig. 1).
A U-shaped relationship was observed between mean
reimbursed expenditure and age, which is likely to be
related to insulin therapy for people with type 1 diabetes at
a younger age due to progression of the disease over time
and the development of complications, as well as other
diseases. Patients with diabetes under the age of 16 years
received a mean reimbursement of €7000 (Table 3) versus
€5500 for patients between the ages of 16 and 45 years and
€6000 for patients between the ages of 46 and 65 years. In
2012, people with diabetes 65 years and older received a
mean reimbursed expenditure of €7300. The mean reim-
bursement of insulin-treated patients was €12,200 versus
€5200 for other people with diabetes. Finally, mean reim-
bursed expenditure for patients living in areas with the
lowest socioeconomic index was €6845 versus €6469 for
those living in territories with the highest socioeconomic
index. This difference cannot be explained by differences
in mean age, which was equal to 66 years in these two
types of territories.
A very widely dispersed distribution of reimbursements
paid to patients with diabetes was observed. Although the
mean reimbursement was €6714/year, the median was only
€2526 in 2012. 10% of patients with diabetes received
more than €16,673 and 5% received more than €25,856.
Table 1 Allocation of diabetes-related reimbursements
Method Scope of health insurance reimbursements Results
Method
1
Reimbursements in the population with diabetes See ‘‘Global comprehensive approach: reimbursements
paid to patients with diabetes’’
Method
2
Medicalized approach: reimbursements specific to diabetes
• Endocrinologist visits, dip-sticks, insulin pens and insulin pump
materials, reimbursements of antidiabetic drugs (oral and insulin),
reimbursements of blood glucose and glycated hemoglobin, Medicine,
Surgery, and Obstetrics (MSO) hospital stays for diabetes
See ‘‘A global medicalized and incremental definition:
diabetes-related reimbursed expenditure in France’’
Method
3.1
Incremental definition: Regression-based approach
• Estimation of the determinants of the level of health care expenditure as a
function of diabetes by controlling for individual characteristics.




Incremental definition: Matched-control approach
• Comparing all medical expenditure of patients with and patients without
diabetes by gender and by 10-year age-groups




Combination of medicalized and matched-control incremental approaches See ‘‘A global medicalized and incremental definition:
diabetes-related reimbursed expenditure in France’’
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The concentration of reimbursements was therefore par-
ticularly high, with 10% of patients with diabetes (280,000
people) concentrating 51% of the €19 billion of reim-
bursements, 5% concentrating 35% of reimbursements and
1% concentrating 14%.
Regression-based incremental approach: spending
attributable to diabetes
Results from the GLM regression estimates are shown in
Appendix 1. The fit of the model was assessed by using the
goodness-of-fit Pearson’s Chi-square test, which was not
statistically significant. The hypothesis of independence
between the observed values and those estimated by the
model assessing the fit of the selected model was then
rejected.
The results of the fitted model were used to calculate the
per-person spending attributable to diabetes (Table 4). The
average spending attributable to diabetes clearly increased
with age. For people 80 years and older, this expenditure
was €6539 versus €3387 for the 50-59 age-group. Based on
the average spending attributable to diabetes, the aggregate
healthcare spending related to diabetes was €11.3 billion
(all schemes).
Incremental definition: matched-control approach
The additional expenditure measured by the matched-con-
trol approach corresponds to expenditure directly related to
the treatment of diabetes, but also expenditure indirectly
related to diabetes, for example expenditure related to obe-
sity, a major risk factor for diabetes, or social deprivation,
which can make the management of diabetes more complex
and which is also linked to obesity and type 2 diabetes.
According to this approach, the financial burden of diabetes
was €7.7 billion (Table 5) with 58% due to outpatient care,
22% due to hospital care and 20% due to drugs.
Table 2 General descriptive statistics of the SNIIRAM database Source: CNAMTS\SNIIRAM
Study population: General Health
Scheme and Local schemes
Patients with diabetes
(type 1 or 2)
Number of patients 59 million 2.9 million
Proportion of women 54% 48%
Age
Mean age 39 years 66 years
Median age 38 years 66 years
Expenditure
Total reimbursed expenditure €124 billion €19 billion
Mean reimbursement per individual €2199 €6714
Ecological deprivation index




Q5 (people living in territories with the lowest socioeconomic index) 20% 25%
Complementary universal health insurance coverage for the
less well off (CMU-C)






















Fig. 1 Breakdown of reimbursements to patients with diabetes
Source: CNAMTS\SNIIRAM 2012
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A global medicalized and incremental definition:
diabetes-related reimbursed expenditure in France
Estimation of the reimbursed expenditure related
to the management of diabetes
According to the medicalized approach, the total diabetes-
specific reimbursed expenditure (see Table 1 for a list of
diabetes-specific expenditure) was €2.3 billion in 2012
(Table 5). The excess reimbursements paid to patients with
diabetes for all non-diabetes-specific expenditure repre-
sented €7.7 billion (Table 5). Diabetes-related reimbursed
expenditure therefore represented a total of €10 billion
(Table 5): 23% for diabetes-specific reimbursed expendi-
ture and 77% for excess reimbursements due to diabetes.
Diabetes-related reimbursed expenditure also represented
52% of all expenditure reimbursed to patients with diabetes
(€19 billion). The per-patient cost of diabetes was €3387.
Non-diabetes-related reimbursed expenditure (€9 billion,
the difference between €19 billion, the global reimburse-
ment received by people with diabetes and €10 billion the
cost of diabetes among these €19 billion) corresponded to
expenditure, which, in the absence of diabetes, would have
theoretically been reimbursed to these patients, based on
the expenditure of age- and gender-matched patients
without diabetes.
Antidiabetic drugs (oral hypoglycemic agents or insulin)
represented an expenditure of about €1.1 billion in 2012,
i.e., one-half (49%) of all diabetes-specific expenditure
Table 3 Mean reimbursements to patients with diabetes in 2012
Source: CNAMTS\SNIIRAM 2012
Mean reimbursement paid by
general health scheme and local
schemes
Age
Less than 16 years €6986
16–45 years €5514
46–64 years €6015
65 years and older €7324
Ecological deprivation index















10% of patients with diabetes More than €16,673 (51% of total
reimbursements paid to patients
with diabetes)
5% of patients with diabetes More than €25,856 (35%)
1% of patients with diabetes More than €59,748 (14%)
Table 4 Estimated aggregate
and mean economic burden of





Total expenditure attributable to diabetes
(95% CI)
Mean expenditure attributable to diabetes
(95% CI)
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(€2.3 billion, see Fig. 2). Insulin therapy accounted for
€400 million of this total €1.1 billion expenditure. Dia-
betes-specific medical devices (e.g., dip-sticks, insulin
pens, insulin pump necessary materials) represented an
expenditure of about €793 million, i.e., 35% of all diabetes-
specific expenditure. Hospital stays specifically for dia-
betes represented a moderate share of diabetes-specific
reimbursed expenditure (€270 million, i.e., 12% of dia-
betes-specific expenditure). Other types of expenditure,
such as blood glucose and glycated hemoglobin assays,
podiatrist fees, or endocrinologist visits (private practice
and outpatient visits) represented a marginal share of dia-
betes-specific expenditure (4%).
Burden of complications, nursing care, and sick
leave
Cardiovascular diseases constitute a major complication or
comorbidity of diabetes [26]. More than one quarter of
patients with diabetes suffer from cardiovascular disease.
The high prevalence of this disease in the population with
diabetes as well as the more complex management due to
the presence of comorbidities can explain a higher mean
annual reimbursed expenditure for health care related to
cardiovascular diseases for patients with diabetes com-
pared to other patients. For example, for men over the age
of 80 years, the mean reimbursed expenditure for drug
treatments of hypertension was €114 for men without
diabetes and €200 for men with diabetes (Table 6). Over-
all, by summing the excess reimbursements paid to the
overall population with diabetes of all ages, the estimated
diabetes-related reimbursed expenditure for antihyperten-
sive drugs was €330 million, i.e., 20% of all reimburse-
ments for these drugs (Table 7). Using the same
methodology as for antihypertensive drugs, the diabetes-
related excess reimbursed expenditure for lipid-lowering
drugs was €240 million. Finally, the excess expenditure for
all drugs used in the management of cardiovascular disease
(antihypertensive, antiplatelet and lipid-lowering drugs,
treatments for heart failure and peripheral artery disease)
represented 7% of the financial burden of diabetes, i.e.,
€697 million.
Another important diabetes-related complication, renal
failure, was associated with high hospital stay expenditure.
The diabetes-related excess reimbursements for hospital
stays due to end-stage renal disease represented €279
million, i.e., 30% of all reimbursements paid for this dis-
ease to hospitals. The expenditure related to nephrologist
visits attributed to diabetes (€6.3 million) represented 21%
of all nephrologist visit expenditure. The last complication
frequently associated with diabetes, diabetic foot ulcers and
amputations, induced excess reimbursements of €112
million, i.e., almost one-half of all expenditure reimbursed
for these diagnoses.
Nursing care expenditure presented a particularly high
proportion of the expenditure due to the excess reim-
bursements to patients with diabetes that amounted to €1.4
billion, i.e., 30% of all reimbursed nursing care expendi-
ture. For women with diabetes over the age of 80 years, the
mean nursing care reimbursement was €1938 versus €629
for an age-matched woman without diabetes. Thus, in this
age-group, the total reimbursed nursing care expenditure
attributable to diabetes, i.e., induced by the excess reim-
bursements paid to women with diabetes of this age, was
€377 million. The great majority of elderly patients treated
with insulin, who are not always able to perform their
injections by themselves, can partly explain this high use of
nursing care in France.
Finally, diabetes and its complications can require
intensive treatments that decrease the patient’s working
capacity, leading to the payment of a cash allowance by
















Reimbursements specific to diabetes
Antidiabetic drugs (€ 1,100 million )
Medical devices for diabetic patients (€ 800 
million)
Hospital care for diabetes (€ 300 million)
Blood tests (€ 60 million)
Endocrinologist visists (€ 30 million)
Podiatric care specific to diabetes (€ 10 million)
Blood glucose tests (€ 8 million)
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disability pensions), in the smaller proportion of people in
working-age groups. For example, a man with diabetes
between the ages of 50 and 59 years received an average of
€1861 of sick leave payments versus €916 (less than half)
for an age-matched man without diabetes. The global
excess payment of daily allowances to patients with dia-
betes represented a total of €528 million.
Discussion and conclusions
The fourmethodologies used in this study provided a range of
different economic estimates of the burden of diabetes. Each
method provides specific insight for policymakers to enhance
diabetes management. Using a new, combined approach,
diabetes-related reimbursed expenditure was estimated to be
about €10 billion. We calculated that care for diabetes com-
plications (cardiovascular diseases, chronic renal failure,
diabetic foot ulcers, and amputations) and additional treat-
ments accounted for the majority of the cost of diabetes care
(€7.7 billion, 77%). Hospitalization for ischemic heart disease
and heart failure accounted for €510 million. This result
highlights the economic impact of cardiovascular risk pre-
vention by monitoring HbA1c, lipids and blood pressure, but
also by preventing smoking and obesity among patients with
diabetes. Pay for performance programmes targeting general
practitioners or disease management programmes for patients
with diabetes could include these objectives in order to
enhance follow-up of people with diabetes. These pro-
grammes may have a positive impact on the health status of
patients with diabetes and, in the long term, should lower the
overall health care expenditure by decreasing the number of
events related to complications [27, 28].
Drugs (about €1.1 billion) represented one-half of the
estimated cost of diabetes according to the medicalized
approach. From a decision-maker’s point of view, this
conclusion highlights the importance of promoting the
most cost-effective drugs. The increasing variety of avail-
able pharmacological agents requires guidelines compris-
ing therapeutic strategies that take these qualities into
account. In France, the Haute Autorite´ de Sante´ (French
Health Authority) released guidelines in 2013 recom-
mending the use of metformin as first-line monotherapy.
When dual therapy is required, the recommended first-line
treatment is a combination of metformin and sulphony-
lurea. Insulin is the treatment of choice when oral therapy
does not achieve the glycemic target. In 2015 the National
Institute for Health and Care Excellence (NICE) published
new guidelines, in which the costs of drugs were explicitly
taken into account to choose the therapeutic strategy. These
guidelines clearly state that if two drugs in the same class
are appropriate, one should choose the option with the
lowest acquisition cost. In line with the NICE guidelines,
the Caisse Nationale d’Assurance Maladie des Travailleurs
Salairie´s (French National Health Insurance, CNAMTS),
after consulting the French Health Authority, published
comparisons of average treatment costs of various treat-
ment strategies as well as comparisons of the price dif-
ference within each strategy between brand-name and
generic drugs [29].
The high level of nursing care expenditure due to dia-
betes provides a different insight into the importance of
developing new ways to provide care to insulin-treated
patients, particularly elderly patients [30, 31], as, in the
context of an ageing population and a high level of fee for
services payment of nursing care, the growing number of
patients on insulin will have a major impact on nursing care
expenditure. Innovations promoting patient autonomy
could be of particular interest. In this case, innovations may
lead to productivity gains, contrary to the predictions of
Baumol’s disease effect, which explains part of the
increase of health care expenditure [32]. According to
Baumol, productivity growth through innovation in the
health care sector is often thought to be slower than in most
other industries, partly because much of this expenditure
concerns health care professional services. For this reason,
the relative cost of health care tends to increase over time
in relation to other consumer products—a phenomenon
often referred to as the cost disease effect. A review of the
payment system for nurses caring for insulin-treated
patients in France could also be initiated. Firstly, bundled
payment could replace fee for services payments of nurses
when they provide long-term care for people with diabetes.
Furthermore, National Health insurance could require
evaluation of the rationale of a nurse’s intervention after a
defined duration of treatment.
Table 5 Allocation of diabetes-
related reimbursements paid by
the general health scheme and
local schemes Source:
CNAMTS\SNIIRAM 2012
Method Scope of health insurance reimbursements Results
Method 1 Reimbursements within the population with diabetes €19 billion
Method 2 Medicalized approach: reimbursements specific to diabetes €2.3 billion
Method 3.1 Incremental definition: regression-based approach €9.8 billion
Method 3.2 Incremental definition: matched-control approach €7.7 billion
Method 4 Combination of medicalized and matched-control incremental approaches €10 billion
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From a methodological perspective, the comprehensive
approach provides an upper bound for the estimation of
cost of illnesses. It provides an accurate picture of the
overall expenditure of the population with a given disease.
It also provides insight into the importance of top spenders:
1% of patients with diabetes accounted for 14% of the total
expenditure of all patients. A particular focus on this
population could help to curb the growth of health care
expenditure for patients with diabetes.
The use of a medical and administrative database allows
precise analysis of expenditure and identifies the types of
expenditure providing the greatest contribution to the
economic burden of diabetes. However, the limited number
of sociodemographic variables may affect the results
obtained by incremental approaches, as the estimated
coefficient could be biased if variables highly correlated to
diabetes are not available. The economic burden of
diabetes could then be either underestimated or overesti-
mated. For example, obesity is a strong risk factor for
diabetes, and a low socio-economic level is associated with
obesity and therefore with diabetes [16]. However, a low
socioeconomic level may also be linked with other
behaviors—smoking for example—or decreased or
increased use of health care. Another example is that of
genetic factors, which are also strong determinants of
diabetes, and which display marked variability between
ethnic groups. People belonging to certain specific ethnic
groups may be more likely to develop diabetes, as well as
other non-diabetes related diseases. They may also be
derived from a lower socioeconomic background. To run a
sensitivity test, we added to the control vector, surrogate
variables a proxy of the individual’s financial situation and
the ecological deprivation index [17] only available for
metropolitan France after excluding the overseas territories
Table 6 Mean reimbursements
for patients with and without
diabetes and excess
reimbursements due to diabetes
Source: CNAMTS\SNIIRAM
2012











Men 80 years and older €268 €195 €14 million
Women 80 years and older €310 €223 €25 million
Drugs
Antihypertensive drugs
Men 80 years and older €200 €114 €17 million
Women 80 years and older €209 €111 €28 million
Lipid-lowering drugs
Men 80 years and older €122 €68 €11 million
Women 80 years old and
over
€100 €46 €16 million
Auxiliaries
Nurses
Men 80 years and older €1292 €453 €164 million
Women 80 years and older €1938 €629 €377 million
Sick leave payments
Men 50–59 years old €1861 €916 €278 million
Women 50–59 years old €1111 €690 €98 million
Hospital
End-stage renal disease
Men 80 years and older €194 €87 €21 million
Women 80 years and older €124 €32 €27 million
Ischemic heart disease
Men 80 years and older €172 €102 €14 million
Women 80 years and older €93 €43 €14 million
Stroke
Men 80 years and older €106 €77 €6 million
Women 80 years and older €94 €68 €8 million
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for which it is not available. The economic burden of
diabetes in metropolitan France was €10.7 billion when age
and sex were introduced as the only control variables, but
€10.3 billion when the ecological deprivation index was
added. In the absence of control for the economic situation,
the coefficient associated with diabetes was therefore
probably overestimated. Other variables such as BMI,
smoking, ethnicity, etc., were not available to be tested.
Nevertheless, joint confounders may affect both the inci-
dence of diabetes and the incidence of other diseases. The
cost associated with diabetes could therefore be overesti-
mated by not adjusting for these variables.
The matched-control approach, which compares the
health care expenditure of subjects with and without the
disease and attributes the differences to the cost of illness,
requires the use of a reasonably comparable control group.
Sensitivity analysis was conducted in order to test the
impact of choosing 10-year age-groups instead of 5-year
age-groups. No significant difference was observed,
thereby confirming the robustness of our results. In a recent
article about the cost of head and neck cancers in the
United States [12], the matching variables used were age,
sex, race, insurance status, the number of priority medical
conditions (proxy for comorbidities) and year of data col-
lection. We restricted the matching variables to age and
sex, as race is not available in our database in which all
individuals are insured by the national health insurance
scheme. We did not add a proxy for comorbidities, as we
considered age to be a good proxy to control for comor-
bidities for patients with diabetes [33]. A regional analysis
of diabetes expenditure using the same methodology was
also performed, but the results are not presented in this
paper. Our results were compared with those based on the
same database (Sniiram), but using a top-down approach
[34]. In this study, based on the same population (French
population covered by the health insurance general
scheme), in 2012, €6.2 billion were attributed to direct
management of diabetes and its complications except for
cardiovascular complications, end-stage renal diseases or
gestational diabetes, which were estimated separately. The








Excess reimbursements due to
diabetes [percentage of
all expenditure for
patients with diabetes (according
to the type of expenditure)]
Proportion of the excess reimbursement




General practitioner €627 million €279 million (44%) 5.5
Cardiologist €37 million €16 million (43%) 9.4
Ophthalmologist €27 million €10 million (37%) 3.9
Nephrologist € 9 million €6 million (67%) 21.3
Drugs
Antiplatelet drugs €131 million €82 million (63%) 20.1
Antihypertensive drugs €519 million €330 million (64%) 19.4
Lipid-lowering drugs €371 million €240 million (65%) 20.3
Heart disease and peripheral artery disease €101 million €45 million (45%) 19.0
Lucentis (ranibizumab) €72 million €22 million (31%) 6.6
Medical devices
Obstructive sleep apnea devices €117 million €82 million (70%) 22.5
Laboratory tests
Cholesterol assays and renal function tests €46 million €28 million (61%) 13.4
Auxiliaries
Nurses €1865 million €1425 million (76%) 30.3
Physiotherapists €367 million €99 million (27%) 3.5
Hospital
Foot ulcer/amputation €131 million €112 million (85%) 44.8
End-stage renal disease €362 million €279 million (77%) 29.9
Chronic renal failure—acute renal failure €171 million €106 million (62%) 16.8
Ischemic heart disease €317 million €188 million (59%) 17.5
Heart failure €196 million €124 million (63%) 21.3
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results of this study were also broadly consistent with those
of earlier studies [6, 35], although it is difficult to perform
more detailed comparisons, particularly due to differences
in time (1999 or 2007 cost data), but also differences in
population definitions and data sources (survey and then
extrapolation to the French population). It could also have
been interesting to apply the new methodology, a preva-
lence-based top-down regression approach, developed for
cost-of illness studies based on massive recently published
data [36]. This method was not available at the time of our
study, but it would also required preliminary adaptations
and tests in order to assess, in particular, the feasibility for
application on a database comprising information about 59
million individuals. This could be the subject of further
investigations on cost-of-illness methods.
This study highlights robust methods that can be used to
estimate the cost of diabetes. These methods provide policy-
makers with diverse and accurate information on the compo-
nents of the cost of diabetes and therefore shed new light on the
debate concerning the public policies to be implemented. In this
context, the static approach (2012) to the financial burden of
diabetes adopted in this study could be usefully completed by a
dynamic approach taking into account the growth of expendi-
ture in relation to the increasing prevalence of the disease and
particularly the development of diabetic complications. By
validating these various methods, this study demonstrates the
value of using thesemethods for other chronic diseases in order
to improve the management of chronic diseases.
Acknowledgements The authors would like to thank the participants
at the ‘‘ISPOR 18th Annual European Congress’’ and the 2016
European Diabetes Epidemiology Group conference for helpful
comments and the participants of the CNAMTS working group on the
cost of diabetes, B. Detournay, V. Raymond, R. Legal, B. Dervaux
and A-L. Couilleraud, C. Gissot and D. Polton.
Compliance with ethical standards
Funding None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use, distri-
bution, and reproduction in anymedium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Roglic, G.: WHO Global report on diabetes: A summary. Int.
J. Non-Commun. Dis. 1, 3–8 (2016)
2. OECD: Panorama de la sante´ 2015 | OECD READ edition, http://
www.keepeek.com/Digital-Asset-Management/oecd/social-issues-
migration-health/panorama-de-la-sante-2015_health_glance-2015-
fr, (2015). Accessed 8 Feb 2017
3. Shaw, J.E., Sicree, R.A., Zimmet, P.Z.: Global estimates of the
prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin.
Pract. 87, 4–14 (2010)
4. Dossou, Y., Roudier, C., Penfornis, A., Fagot-Campagna, A.,
Druet, C.: Characteristics, vascular risk, frequency of complica-
tions, and quality of care in people with type 1 diabetes in
mainland France. ENTRED 2001 and ENTRED 2007. Bull.
Epide´miol. Hebd. 37–38, 477–484 (2013)
5. Fagot-Campagna, A., Weill, A., Paumier, A., Poutignat, N.,
Fournier, C., Fosse, S., Roudier, C., Romon, I., Chantry, M.,
Detournay, B., Eschwe`ge, E., Rudnichi, A., Druet, C., Halimi, S.:
Que retenir du bilan d’ENTRED 2007–2010? Me´d. Mal. Me´ta-
boliques. 4, 212–218 (2010)
6. Ricci, P., Chantry, M., Detournay, B., Poutignat, N., Kusnik-
Joinville, O., Raimond, V., Thammavong, N., Weill, A.: Analyse
e´conomique des soins des personnes traite´es pour diabe`te (Etudes
Entred 2001 et 2007). Prat. Organ. Soins. 41, 1–10 (2010)
7. Ricci, P., Blotie`re, P.-O., Weill, A., Simon, D., Tuppin, P.,
Ricordeau, P., Allemand, H.: Diabe`te traite´: quelles e´volutions
entre 2000 et 2009 en France. Bull. Epidemiol. Hebd. 42,
425–431 (2010)
8. Akobundu, E., Ju, J., Blatt, L., Mullins, C.D.: Cost-of-illness
studies: a review of current methods. PharmacoEconomics 24,
869–890 (2006)
9. Onukwugha, E., McRae, J., Kravetz, A., Varga, S., Khairnar, R.,
Mullins, C.D.: Cost-of-illness studies: an updated review of
current methods. PharmacoEconomics 34, 43–58 (2016)
10. Honeycutt, A.A., Segel, J.E., Hoerger, T.J., Finkelstein, E.A.:
Comparing cost-of-illness estimates from alternative approaches:
an application to diabetes. Health Serv. Res. 44, 303–320 (2009)
11. Arredondo, A., Barcelo´, A.: The economic burden of out-of-
pocket medical expenditures for patients seeking diabetes care in
Mexico. Diabetologia 50, 2408–2409 (2007)
12. Coughlan, D., Yeh, S.T., O’Neill, C., Frick, K.D.: Evaluating
direct medical expenditures estimation methods of adults using
the medical expenditure panel survey: an example focusing on
head and neck cancer. Value Health J. Int. Soc. Pharmacoecon.
Outcomes Res. 17, 90–97 (2014)
13. Seuring, T., Archangelidi, O., Suhrcke, M.: The economic costs
of type 2 diabetes: a global systematic review. PharmacoEco-
nomics 33, 811–831 (2015)
14. Arredondo, A., De Icaza, E.: The cost of diabetes in Latin
America: evidence from Mexico. Value Health J. Int. Soc.
Pharmacoecon. Outcomes Res. 14, S85–S88 (2011)
15. Tuppin, P., de Roquefeuil, L., Weill, A., Ricordeau, P., Merlie`re,
Y.: French national health insurance information system and the
permanent beneficiaries sample. Rev. Epidemiol. Sante Publique
58, 286–290 (2010)
16. Mandereau-Bruno,L.,Denis, P., Fagot-Campagna,A., Fosse-Edorh,
S.: Pre´valence du diabe`te traite´ pharmacologiquement et disparite´s
territoriales en France en 2012, http://invs.santepubliquefrance.fr/
beh/2014/30-31/2014_30-31_1.html, (2014). Accessed 8 Feb 2017
17. Rey, G., Jougla, E., Fouillet, A., He´mon, D.: Ecological association
between a deprivation index andmortality in France over the period
1997–2001: variations with spatial scale, degree of urbanicity, age,
gender and cause of death. BMC Public Health 9, 33 (2009)
18. Haut Conseil de la Sante´ Publique: Indicateurs de suivi des ine´-
galite´s sociales de sante´, http://www.hcsp.fr/Explore.cgi/Tele
charger?NomFichier=hcspr20130619_indicateurinegalitesociale
sante.pdf. Accessed 8 Feb 2017
19. Trogdon, J.G., Murphy, L.B., Khavjou, O.A., Li, R., Maylahn,
C.M., Tangka, F.K., Nurmagambetov, T.A., Ekwueme, D.U.,
Nwaise, I., Chapman, D.P., Orenstein, D.: Costs of chronic dis-
eases at the state level: the chronic disease cost calculator. Prev.
Chronic. Dis. 12, E140 (2015)
G. Lagasnerie et al.
123
20. Jones, A.M.: Health econometrics. In: Culyer, A.J., Newhouse,
J.P. (eds) Handbook of Health Economics, pp. 265–344. Elsevier
(2000)
21. Manning, W.G., Mullahy, J.: Estimating log models: to transform
or not to transform? J. Health Econ. 20, 461–494 (2001)
22. Albouy, V., Davezies, L., Debrand, T.: Health expenditure
models: a comparison using panel data. Econ. Model. 27,
791–803 (2010)
23. Ricordeau, P., Weill, A., Vallier, N., Bourrel, R., Schwartz, D.,
Guilhot, J., Fender, P., Allemand, H.: The prevalence and cost of
diabetes in metropolitan France: what trends between 1998 and
2000?*. Diabetes Metab. 29, 497–504 (2003)
24. Dall, T., Mann, S., Zhang, Y., Martin, J., Chen, Y., Hogan, P.:
Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36,
1033–1046 (2013)
25. INSERM: Obe´site´, http://www.inserm.fr/thematiques/physio
pathologie-metabolisme-nutrition/dossiers-d-information/obesite.
Accessed 8 Feb 2017
26. Moisan, C., Charles, M.-A., Crine, A., Basdevant, A., Eschwe`ge,
E.: P2071 Le diabe`te de type 2 en France en 2012; donne´es de
l’enqueˆte ObEpi. Diabetes Metab. 39, A85 (2013)
27. Hamar, G.B., Rula, E.Y., Coberley, C., Pope, J.E., Larkin, S.:
Long-term impact of a chronic disease management program on
hospital utilization and cost in an Australian population with
heart disease or diabetes. BMC Health Serv. Res. 15, 174 (2015)
28. Jiao, F., Fung, C.S.C., Wan, Y.F., McGhee, S.M., Wong, C.K.H.,
Dai, D., Kwok, R., Lam, C.L.K.: Long-term effects of the mul-
tidisciplinary risk assessment and management program for
patients with diabetes mellitus (RAMP-DM): a population-based




Accessed 8 Feb 2017
30. Hendra, T.J.: Starting insulin therapy in elderly patients. J. R.
Soc. Med. 95, 453–455 (2002)
31. Ober, S.K., Watts, S., Lawrence, R.H.: Insulin use in elderly
diabetic patients. Clin. Interv. Aging 1, 107 (2006)
32. Baumol, W.J.: Macroeconomics of unbalanced growth: the
anatomy of urban crisis. Am. Econ. Rev. 57, 415–426 (1967)
33. Cosker, K., Denis, P., Tala, S., Rigault, A., Rivie`re, S., Pestel, L.,
Tuppin, P., Fagot-Campagna, A.: Associated pathologies, health
conditions and treatments among French people with diabetes in




2016.pdf. Accessed 8 Feb 2017
35. Jo¨nsson, B.: Revealing the cost of type II diabetes in Europe.
Diabetologia 45, S5–S12 (2002)
36. Stollenwerk, B., Welchowski, T., Vogl, M., Stock, S.: Cost-of-
illness studies based on massive data: a prevalence-based, top-
down regression approach. Eur. J. Health Econ. HEPAC Health
Econ. Prev. Care. 17, 235–244 (2016)
The economic burden of diabetes to French national health insurance: a new cost-of-illness…
123
